B2i Digital (@b2idigital)

Precipio, Inc. (@PrecipioDx ) (@Nasdaq : $PRPO ) reported revenue of $7.0 million for the second quarter ended June 30, 2026, the highest quarterly revenue in the company’s history and an increase of 22% from $5.7 million in the second quarter of 2025. The specialty cancer diagnostics company validates its technologies clinically in its own laboratory before commercializing them for the global laboratory community. Precipio, Inc. is a B2i Digital (@b2idigital )Featured Company. See the company’s in-depth profile at: Both sides of the business contributed, with pathology services and diagnostic products each growing sequentially: • Revenue surpassed $7 million for the first time in company history, rising from $6.7 million in the first quarter • Product revenue reached $0.9 million, an increase of 21% over the previous high of $750,000 in the fourth quarter of 2025, and pathology revenue reached $6.1 million • Adjusted EBITDA, a non-GAAP measure the company reconciles in the release, was positive at $0.4 million for the quarter • Cash flow from operations was $0.7 million, and cash ended the quarter above $3 million against $1.1 million a year earlier • Management will discuss the quarter on a shareholder call on August 17, 2026 at 5 p.m. ET, followed by a moderated question and answer session The conference call may be accessed by calling 646.307.1865. All callers should ask for the Precipio Inc. conference call. Regarding the cash balance, Ilan Danieli, Chief Executive Officer of Precipio, stated: “We’ve achieved this level of cash without a financing event, demonstrating the strength of our operations. We’re encouraged by the progress we’ve made and believe we are well positioned to continue building on this momentum.” Read the full release: Precipio is a healthcare biotechnology company focused on cancer diagnostics. Its mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services that deliver higher accuracy, improved laboratory workflow, and better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in its laboratory where it designs, tests, validates, and uses these products clinically, then commercializes them as proprietary products that serve the global laboratory community. More information is available at Discover more emerging growth Featured Companies, Featured Experts, and upcoming Featured Conferences at B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at

Carrier Connect signs definitive agreement for its first U.S. data center platform, with Rochester Colo assets expected to add CAD $885,000 in ARR. Carrier Connect Data Solutions Inc (@CarrierCDS) (TSXV: CCDS | OTCQB: CCDSF) announced today that it has signed a definitive Asset Purchase Agreement, through its wholly owned subsidiary PureColo Inc., to acquire the principal data center assets of Rochester Colo, LLC, a carrier-neutral colocation provider in Rochester, New York. Carrier Connect Data Solutions is a New and Notable company in the B2i Digital (@b2idigital) network. To learn more, visit The proposed acquisition would give Carrier Connect its first U.S. operating platform and sixth data center overall. Rochester Colo serves customers across upstate New York, the broader Northeast, and beyond with secure colocation, power and cooling, network connectivity, physical security, and independently audited operational controls. Rochester Colo is currently generating approximately CAD $885,000 in annual recurring revenue, with more than 60% capacity still available. Upon successful closing, Carrier Connect expects the transaction to increase top-line revenue by approximately 15-17% immediately. Consideration includes USD $250,000 in cash at closing, of which USD $25,000 has already been paid as a deposit, plus 800,000 common shares of Carrier Connect. The shares will be escrowed and released in four equal tranches at 6, 12, 18, and 24 months following closing. The arm’s length transaction carries no finder’s fees and is subject to customary closing conditions, including acceptance by the TSX Venture Exchange. Closing is expected on August 15, 2026, or as otherwise agreed by the parties. Carrier Connect rolls up Tier II/III data centers internationally for AI companies, service providers, enterprises, and small businesses. As a carrier-neutral operator, its systems are fully independent and owned outright within leased space. Principal markets are Vancouver, Ottawa, Saint John, and Perth. The company is led by Mark Binns, CEO; Johan Arnet, CTO; and Mark Alexander, CRO. Full announcement: Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at B2i Digital is not a broker-dealer or investment adviser, and content shared here is for informational purposes only and is not investment advice.

eXoZymes (Nasdaq: EXOZ) (@eXoZymes) announced the pricing of a public offering expected to generate approximately $5.3 million in gross proceeds, with funding intended to support development of its NCT program, continued R&D, and general corporate initiatives. For investors following eXoZymes, the announcement is significant because it provides additional capital to advance the company's AI-enabled exozyme platform and its efforts to scale production of high-value molecules for nutraceutical, pharmaceutical, and specialty chemical markets. eXoZymes is focused on using engineered enzymes operating outside living cells to manufacture complex molecules at commercial scale, an approach the company believes can overcome limitations associated with traditional biomanufacturing methods. Read the full announcement: eXoZymes is a B2i Digital (@b2idigital) Featured Company. See the company’s profile at Disclosure: This post is for informational purposes only and does not constitute investment advice, an offer to sell, or a solicitation to purchase EXOZ or any other security. David Shapiro, CEO of B2i Digital, personally purchased shares of unrestricted EXOZ stock in the open market as part of B2i Digital's practice of investing alongside its Featured Companies. Investors should conduct their own due diligence and consult qualified financial and professional advisors before making any investment decisions.